Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00717236 · ClinicalTrials.gov registry record · Phase 3

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis

A Phase 3 study of Rheumatoid Arthritis, sponsored by UCB Pharma.

Completed
Registry status
Phase 3
Development phase
1,648
Enrollment target
20
Study locations

NCT00717236: Completed Phase 3 study of Rheumatoid Arthritis, sponsored by UCB Pharma.

NCT00717236 is a Phase 3 study of Rheumatoid Arthritis that has completed, run by UCB Pharma. The registered enrollment target is 1,648 participants, below the 4,682-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (65% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00717236, a Phase 3 study of Rheumatoid Arthritis, has completed, sponsored by UCB Pharma.

COMPLETED
Registry status
Phase 3
Development phase
1,648 participants
Enrollment target
20
Study locations

Study Summary

This is a Phase IIIb multicenter study to evaluate the safety and efficacy of certolizumab pegol (CZP) administered to patients with moderate-to-severe rheumatoid arthritis.

Primary Outcome

ACR20 responders are subjects with at least 20% improvement from Baseline for tender joint count (TJC), swollen joint count (SJC), and at least 3 of the 5 remaining core set measures: 1) Health Assessment Questionnaire-Disability Index (HAQ-DI), 2) C-reactive Protein (CRP), 3) Patient's Assessment of Arthritis Pain-Visual Analog Scale (PAAP-VAS), 4) Patient's Global Assessment of Disease Activity-Visual Analog Scale (PtGADA-VAS), 5) Physician's Global Assessment of Disease Activity-Visual Analog

Conditions Studied

Rheumatoid Arthritis

Interventions

  • OTHER Placebo
  • DRUG Certolizumab pegol (CZP)

Study Locations (20)

California

  • - Fullerton
  • - La Jolla
  • - Los Angeles
  • - Palm Desert
  • - Sacramento
  • - Santa Barbara
  • - Santa Maria
  • - Tustin
  • - Westlake Village
  • - Whittier

Alabama

  • - Birmingham
  • - Montgomery

Arizona

  • - Phoenix
  • - Tucson

Arkansas

  • - Hot Springs
  • - Little Rock

Connecticut

  • - Danbury
  • - Trumbull

Colorado

  • - Denver

Delaware

  • - Lewes

Trial Details

FieldValue
Enrollment Target 1,648 participants
Start Date 2008-07
Est. Completion 2011-03
Phase Phase 3
UCB Pharma

100 total trials

What the finished NCT00717236 record still lists

NCT00717236 is an interventional study that assigns participants to a tested intervention. Its 1,648 participants enrollment target places it among the larger protocols in the corpus, below the 4,682-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (65% lower).

The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00717236 names 20 study sites across 7 states, led by California, Alabama, Arizona.

Frequently Asked Questions

What is clinical trial NCT00717236 about?

NCT00717236 is a clinical study titled "Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis". This is a Phase IIIb multicenter study to evaluate the safety and efficacy of certolizumab pegol (CZP) administered to patients with moderate-to-severe rheumatoid arthritis.

What is the current status of trial NCT00717236?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,648 participants. The study started on 2008-07. Estimated completion is 2011-03.

What conditions does trial NCT00717236 study?

This clinical trial studies the following conditions: Rheumatoid Arthritis.

What interventions are being tested in trial NCT00717236?

The interventions under investigation include: Placebo (OTHER), Certolizumab pegol (CZP) (DRUG).

Who is sponsoring clinical trial NCT00717236?

This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00717236 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Rheumatoid Arthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00717236's enrollment target sits among peer trials

1,648 12th of 197 higher than 186 of 197 other Rheumatoid Arthritis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Rheumatoid Arthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04510129 · 1,650 participants

    A Multicenter Cancer Biospecimen Collection Study

  • NCT05612750 · 1,650 participants · NA

    Comparative Effectiveness of Online 8-session CBT vs. 1-Session Empowered Relief for Chronic Pain - The PROGRESS Study

  • NCT06215716 · 1,650 participants · Phase 3

    A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

  • NCT07046260 · 1,650 participants

    Prospective Study to Assess a Diagnostic Aid for Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00717236, the US trial registry maintained by the National Library of Medicine. NCT00717236 (large enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.